JP7108146B2 - 新規メチルキナゾリノン誘導体 - Google Patents

新規メチルキナゾリノン誘導体 Download PDF

Info

Publication number
JP7108146B2
JP7108146B2 JP2021566023A JP2021566023A JP7108146B2 JP 7108146 B2 JP7108146 B2 JP 7108146B2 JP 2021566023 A JP2021566023 A JP 2021566023A JP 2021566023 A JP2021566023 A JP 2021566023A JP 7108146 B2 JP7108146 B2 JP 7108146B2
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
braf
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531609A (ja
Inventor
コジモ ドレンテ，
デーヴィッド スティーブン ヘウィングス，
ダニエル フンツィカー，
ダニエラ クルメナッハ，
ピエルジョルジョ フランチェスコ トンマゾ ペッタッツォーニ，
ユルゲン ヴィヒマン，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority to JP2021202780A priority Critical patent/JP7802514B2/ja
Publication of JP2022531609A publication Critical patent/JP2022531609A/ja
Application granted granted Critical
Publication of JP7108146B2 publication Critical patent/JP7108146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)
JP2021566023A 2019-12-10 2020-12-08 新規メチルキナゾリノン誘導体 Active JP7108146B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021202780A JP7802514B2 (ja) 2019-12-10 2021-12-14 新規メチルキナゾリノン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941.7 2019-12-10
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021202780A Division JP7802514B2 (ja) 2019-12-10 2021-12-14 新規メチルキナゾリノン誘導体

Publications (2)

Publication Number Publication Date
JP2022531609A JP2022531609A (ja) 2022-07-07
JP7108146B2 true JP7108146B2 (ja) 2022-07-27

Family

ID=68848113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566023A Active JP7108146B2 (ja) 2019-12-10 2020-12-08 新規メチルキナゾリノン誘導体
JP2021202780A Active JP7802514B2 (ja) 2019-12-10 2021-12-14 新規メチルキナゾリノン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021202780A Active JP7802514B2 (ja) 2019-12-10 2021-12-14 新規メチルキナゾリノン誘導体

Country Status (29)

Country Link
US (2) US12116349B2 (https=)
EP (2) EP4483882A3 (https=)
JP (2) JP7108146B2 (https=)
KR (1) KR102836833B1 (https=)
CN (2) CN114787156B (https=)
AR (1) AR122351A1 (https=)
AU (1) AU2020403443B2 (https=)
CL (1) CL2022001529A1 (https=)
CO (1) CO2022008968A2 (https=)
CR (1) CR20220251A (https=)
DK (1) DK4073065T3 (https=)
ES (1) ES3023264T3 (https=)
FI (1) FI4073065T3 (https=)
HR (1) HRP20250418T1 (https=)
HU (1) HUE071148T2 (https=)
IL (2) IL316473A (https=)
LT (1) LT4073065T (https=)
MA (1) MA58087B1 (https=)
MX (1) MX2022006783A (https=)
PE (1) PE20221778A1 (https=)
PH (1) PH12022551119A1 (https=)
PL (1) PL4073065T3 (https=)
PT (1) PT4073065T (https=)
RS (1) RS66721B1 (https=)
SI (1) SI4073065T1 (https=)
TW (2) TWI877268B (https=)
UA (1) UA128299C2 (https=)
WO (1) WO2021116055A1 (https=)
ZA (2) ZA202204675B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022124458A (ja) * 2019-12-10 2022-08-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP2023505300A (ja) * 2019-12-10 2023-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
IL307964A (en) * 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
CA3216220A1 (en) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
MX2023014629A (es) * 2021-06-09 2024-01-30 Hoffmann La Roche Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida.
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4426305A1 (en) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Novel use of quinazolinone compound for the treatment of cancer
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4618994A1 (en) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
TW202438072A (zh) * 2022-12-15 2024-10-01 瑞士商赫孚孟拉羅股份公司 製備喹唑啉酮衍生物之方法
KR20260032991A (ko) 2023-07-04 2026-03-10 에프. 호프만-라 로슈 아게 (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
WO2026037755A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
WO2026046946A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP2018515570A (ja) 2015-05-22 2018-06-14 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3147281A1 (en) 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
JP2023554062A (ja) 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
US20250011304A1 (en) 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP2018515570A (ja) 2015-05-22 2018-06-14 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2014年，Vol.24, No.8，p.1923-1927

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022124458A (ja) * 2019-12-10 2022-08-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP2023505300A (ja) * 2019-12-10 2023-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤
JP7788380B2 (ja) 2019-12-10 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤
JP7802514B2 (ja) 2019-12-10 2026-01-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体

Also Published As

Publication number Publication date
UA128299C2 (uk) 2024-05-29
BR112022011123A2 (pt) 2022-08-23
EP4483882A2 (en) 2025-01-01
FI4073065T3 (fi) 2025-04-16
KR102836833B1 (ko) 2025-07-22
SI4073065T1 (sl) 2025-06-30
PL4073065T3 (pl) 2025-05-19
PT4073065T (pt) 2025-04-15
JP2022531609A (ja) 2022-07-07
AR122351A1 (es) 2022-09-07
US20240174621A1 (en) 2024-05-30
MA58087B1 (fr) 2025-04-30
DK4073065T3 (da) 2025-04-22
PH12022551119A1 (en) 2023-08-23
WO2021116055A1 (en) 2021-06-17
JP2022124458A (ja) 2022-08-25
RS66721B1 (sr) 2025-05-30
TWI877268B (zh) 2025-03-21
US20220298119A1 (en) 2022-09-22
AU2020403443A1 (en) 2022-05-12
CA3162883A1 (en) 2021-06-17
HRP20250418T1 (hr) 2025-06-06
CN118791472A (zh) 2024-10-18
PE20221778A1 (es) 2022-11-16
CL2022001529A1 (es) 2023-02-10
JP7802514B2 (ja) 2026-01-20
TWI908405B (zh) 2025-12-11
CN114787156A (zh) 2022-07-22
ZA202204675B (en) 2022-12-21
IL316473A (en) 2024-12-01
TW202504895A (zh) 2025-02-01
AU2020403443B2 (en) 2023-02-23
KR20220110554A (ko) 2022-08-08
CO2022008968A2 (es) 2022-07-19
US12116349B2 (en) 2024-10-15
EP4073065B1 (en) 2025-02-19
LT4073065T (lt) 2025-04-25
MX2022006783A (es) 2022-07-11
EP4073065A1 (en) 2022-10-19
TW202136245A (zh) 2021-10-01
CR20220251A (es) 2022-07-11
CN114787156B (zh) 2024-07-26
ZA202206923B (en) 2024-10-30
ES3023264T3 (en) 2025-05-30
IL292161B2 (en) 2025-04-01
NZ787393A (en) 2025-07-25
IL292161B1 (en) 2024-12-01
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
EP4483882A3 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
JP7108146B2 (ja) 新規メチルキナゾリノン誘導体
CN113966335B (zh) 用于治疗癌症的egfr抑制剂
CN113993590B (zh) 新型egfr抑制剂
JP7737991B2 (ja) Ｅｇｆｒ阻害剤
CA3162883C (en) (3r)-and (3s)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide compounds and their use as braf inhibitors
RU2802968C1 (ru) Новые производные метилхиназолинона
HK40074142A (en) New methylquinazolinone derivatives
RU2818677C2 (ru) Ингибитор egfr для лечения рака
HK40113036A (zh) 新颖甲基喹唑啉酮衍生物
HK40074142B (zh) 新颖甲基喹唑啉酮衍生物
BR112022011123B1 (pt) Composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto
HK40063822A (en) Egfr inhibitor for the treatment of cancer
HK40079554A (en) Egfr inhibitors

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211214

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220714

R150 Certificate of patent or registration of utility model

Ref document number: 7108146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250